Literature DB >> 15013269

Comparative evaluation of D-dimer assays for exclusion of deep venous thrombosis in symptomatic outpatients.

Wolfgang Engelhardt1, Gualtiero Palareti, Cristina Legnani, Erika Gringel.   

Abstract

Diagnostic work-up of patients sent to the hospital for diagnosing of deep venous thrombosis (DVT) often combines the determination of D-dimer and the application of a clinical probability score. To fulfill diagnostic as well as economic needs, D-dimer assays should exhibit a high negative predictive value (NPV) as well as reasonable specificity. In this study, we evaluated both a latex-enhanced immunoassay for use on routine coagulation analyzers and a radial partition immunoassay (RPIA) for use on a point-of-care analyzer. Samples included were from 344 outpatients with suspected deep venous thrombosis. Among them, 100 had deep venous thrombosis. Results obtained for both assays show a good efficiency for exclusion of deep venous thrombosis with well-acceptable specificity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15013269     DOI: 10.1016/j.thromres.2003.11.002

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  2 in total

1.  Reference Values of D-Dimers and Fibrinogen in the Course of Physiological Pregnancy: the Potential Impact of Selected Risk Factors-A Pilot Study.

Authors:  Aldona Siennicka; Magdalena Kłysz; Kornel Chełstowski; Aleksandra Tabaczniuk; Zuzanna Marcinowska; Paulina Tarnowska; Jolanta Kulesza; Andrzej Torbe; Maria Jastrzębska
Journal:  Biomed Res Int       Date:  2020-05-24       Impact factor: 3.411

2.  Validation of STA-Liatest D-Di assay for exclusion of pulmonary embolism according to the latest Clinical and Laboratory Standard Institute/Food and Drug Administration guideline. Results of a multicenter management study.

Authors:  Gilles Pernod; Haifeng Wu; Emmanuel de Maistre; John Lazarchick; Jeannine Kassis; Carlos Aguilar; Pascual M Vera; Gualtiero Palareti; Armando D'Angelo
Journal:  Blood Coagul Fibrinolysis       Date:  2017-04       Impact factor: 1.276

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.